Showing results (141-150 of 152) with videos related to
Sort By:
Pageof 16
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infectionEric Lawitz, Alessandra Mangia, David Wyles, et al.Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.Journal of Hepatology|July 28, 2014
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infectionAndrew J Muir, Sanjeev Arora, Gregory Everson, et al.Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trialsEric Lawitz, Maria Buti, John M Vierling, et al.The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.Pageof 16